Tricalcium silicate, the main constituent of Portland cement, hydrates to produce crystalline calcium hydroxide and calcium-silicate-hydrates (C-S-H) nanocrystalline gel. Tricalcium silicate-based cement, with tantalum oxide has no cytotoxic effect. Tricalcium silicate-based materials are growing in popularity for dental procedures. The use of tricalcium silicate as an odontotropic preparation makes it possible to create a hermetic crown restoration with a high degree of adhesion. The use of the tricalcium silicate as a material for direct pulp capping promotes more active regeneration processes.

Picadex is a dithiocarbamate derivative of piperazine. It was used in veterinary as an antihelmintic drug. It was shown to be effective in the treatment of Oesophagostamum infection in pigs.

Flumethasone 21-acetate is an anti-inflammatory corticosteroid. It has 300 times greater anti-inflammatory activity and 677 times greater capacity to promote liver glycogen deposition than hydrocortisone. It has anti-rheumatic potency 31 times higher than cortisol.

Butyl chloride is an alkyl halide. It is used as a butylating agent in organic synthesis, e.g., in the manufacture of butyl cellulose. n-Butyl chloride is a veterinary antiparasitic (anthelmintic) drug. It is used for the removal of ascarids and hookworms from dogs and cats. n-Butyl chloride is marketed under tradenames NBC Kaps Wormer for dogs, Happy Jack Worm for dogs; Sergeants Sure Shot Capsules for cats and dogs.

Dalvastatin is a synthetic HMG-CoA reductase inhibitor developed by Rhône-Poulenc Rorer. Dalvastatin is a prodrug and is itself an inactive lactone. After oral ingestion, the drug is hydrolyzed in vivo to the corresponding beta-hydroxy acid, which is the pharmacologically active form. HMG-CoA reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway. An active form of dalvastatin inhibits HMG-CoA reductase with IC50 of 3.4 nM. In ex vivo assay, orally administered dalvastatin inhibited cholesterol biosynthesis in rat liver slices with an ED50 value of 0.9. The efficacy of dalvastatin to lower cholesterol was investigated in the clinical trials in the 1990s, but no results were reported.